Modification of the of the cardiometabolic profile using combined therapy of the angiotensin receptor-neprilysin inhibitor and empagliflozin in comorbid patients with Chronic Heart Failure and type 2 Diabetes Mellitus

• DOI: 10.18087/cardio.2020.5.n840
• Publication Date: 2020-06-09T12:38:27Z
• Authors: O. V. Tsygankova; V. V. Veretyuk; V. Yu. Mareev
• Keywords: Empagliflozin; Sacubitril

Chronic heart failure (CHF) and type 2 diabetes mellitus (DM2) very common comorbidities with bidirectional, mutually aggravating courses. DM2 is known as an independent risk factor of cardiovascular complications whereas a higher CHF functional class associated increased DM2. At present time, hypoglycemic drugs the gliflozin angiotensin receptor-neprilysin inhibitor (ARNI) are widely discussed in connection their use treatment patients DM. The PARADIGM-HF study investigated effects long-term reduced ejection fraction presently only representative ARNI class, single supramolecular complex valsartan-sacubitril. This medicine has already exceled enalapril at effect not on incidence nonfatal fatal events but also general mortality. Mean age included into that was 63.8±11.5 years; 21 % them were females. In real-life clinical practice, physicians more frequently see older patients, most females, particularly On other hand, sodium-glucose cotransporter-2 inhibitors, including empagliflozin, significantly decreased death rate frequency exacerbations concomitant diseases, CHF. article describes case initiating valsartan-sacubitril combination empagliflozin elderly female patient congestive intermediate (EF) comorbidities, history myocardial infarction Of interest rapid positive dynamics clinical, laboratory (NT-proBNP) instrumental (echocardiography) markers 3 months, EF "recovered" from to preserved during comprehensive cardio-reno-metabolic approach. Both cardiologists endocrinologists should definitely consider this approach managing such since current cardiological have additional pleiotropic metabolic drugs, turn, influence prognosis.